Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.420
-0.030 (-2.07%)
At close: Jun 8, 2026, 4:00 PM EDT
1.440
+0.020 (1.41%)
After-hours: Jun 8, 2026, 7:53 PM EDT

Coherus Oncology Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2191721603746161,228
Market Cap Growth
143.91%7.83%-57.30%-39.34%-49.83%-2.58%
Enterprise Value
106.3638.42301.77734.63900.421,226
Last Close Price
1.421.421.383.337.9215.96
PE Ratio
0.930.995.52---
PS Ratio
4.674.086.051.452.923.76
PB Ratio
2.792.82-1.21-1.93-4.4812.56
P/TBV Ratio
2.212.73-1.20-1.62-4.4712.32
EV/Sales Ratio
2.270.9111.442.864.273.75
Debt / Equity Ratio
0.480.63-2.03-2.47-3.464.25
Net Debt / Equity Ratio
-1.64-2.19-1.08-1.87-2.07-0.02
Net Debt / EBITDA Ratio
1.650.75-0.73-1.81-1.120.01
Net Debt / FCF Ratio
0.760.97-6.96-2.06-1.180.04
Asset Turnover
0.080.120.050.460.360.43
Inventory Turnover
1.783.740.263.141.831.41
Quick Ratio
1.431.360.881.142.173.27
Current Ratio
1.561.471.211.432.753.64
Return on Equity (ROE)
266.79%-473.47%-17.52%143.81%1470.09%-151.62%
Return on Assets (ROA)
-31.29%-51.25%-37.04%-36.54%-44.28%-34.70%
Return on Invested Capital (ROIC)
-146.98%-228.44%-139.11%-122.75%-207.76%-209.70%
Return on Capital Employed (ROCE)
-65.20%-127.78%-86.17%-63.50%-60.01%-43.61%
Earnings Yield
85.04%100.70%18.12%---
Buyback Yield / Dilution
-6.02%-2.26%-21.66%-21.30%-2.89%9.63%
Total Shareholder Return
-6.02%-2.26%-21.66%-21.30%-2.89%9.63%
SEC Filings: 10-K · 10-Q